Take Our 5-Minute Quiz to See if You Qualify. Free Shipping on All Medications

Take Our 5-Minute Quiz to See if You Qualify. Free Shipping on All Medications

Take Our 5-Minute Quiz to See if You Qualify. Free Shipping on All Medications

Christine Folake Obasi-Coon, PharmD

Christine Folake Obasi-Coon, PharmD

Christine Folake Obasi-Coon, PharmD

Licensed Pharmacist and Compounding Specialist

Christine is a licensed pharmacist with specialized expertise in pharmaceutical compounding and medical weight management, focused on creating personalized medication solutions.

Professional Background

Christine Folake Obasi-Coon is a licensed pharmacist in Texas with expertise in pharmaceutical compounding and medical weight management. As a compounding specialist, she focuses on creating customized medication formulations tailored to individual patient needs. Her professional experience includes developing personalized treatment approaches that address specific health challenges.

Education & Credentials

  • Doctor of Pharmacy (PharmD)

  • Licensed Pharmacist in the State of Texas

  • Specialized Training in Pharmaceutical Compounding

Areas of Expertise

  • Pharmaceutical Compounding: Creating personalized medication formulations that address individual patient needs

  • Medical Weight Management: Expertise in pharmaceutical approaches to weight management

  • Medication Customization: Developing alternative dosage forms and combinations to improve patient outcomes

  • Pharmaceutical Patient Education: Helping patients understand their medications and treatment plans

Professional Philosophy

"I believe that effective pharmaceutical care should be personalized to each individual's unique needs. Through a patient-centered approach, I work to ensure that medication solutions are both clinically effective and practical for real-world implementation."

*Based on a 78-week clinical trial; patients without diabetes lost with a BMI of ≥30, or ≥27 but at average of 15% of their body weight^1 (15.8 lbs) on 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. Individual results may vary.

*Based on a 78-week clinical trial; patients without diabetes lost with a BMI of ≥30, or ≥27 but at average of 15% of their body weight^1 (15.8 lbs) on 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. Individual results may vary.

*Based on a 78-week clinical trial; patients without diabetes lost with a BMI of ≥30, or ≥27 but at average of 15% of their body weight^1 (15.8 lbs) on 2.4 mg semaglutide, when combined with a reduced-calorie diet and increased physical activity. Individual results may vary.